ERBB2 and breast cancer: This effect has been observed in FGFR2 driven endometrial cancer cell lines with acquired resistance to FGFR inhibition and ERBB2 amplified breast cancer cells treated with anti-HER2 therapy suggested PLHDA1 may be a common resistance mechanism in RTK driven cancers[62].